• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . Transcriptomic analysis after SARS-CoV-2 mRNA vaccination reveals a specific gene signature in low-responder hemodialysis patients

tetano

Editor, Senior Moderator
Front Immunol


. 2025 Apr 30:16:1508659.
doi: 10.3389/fimmu.2025.1508659. eCollection 2025. Transcriptomic analysis after SARS-CoV-2 mRNA vaccination reveals a specific gene signature in low-responder hemodialysis patients

Simone Lucchesi[SUP] 1 [/SUP], Giorgio Montesi[SUP] 1 [/SUP], Jacopo Polvere[SUP] 1 [/SUP], Fabio Fiorino[SUP] 1 2 [/SUP], Gabiria Pastore[SUP] 1 [/SUP], Margherita Sambo[SUP] 3 4 [/SUP], Marialetizia Lusini[SUP] 5 [/SUP], Francesca Montagnani[SUP] 3 4 [/SUP], Annalisa Ciabattini[SUP] 1 [/SUP], Francesco Santoro[SUP] 1 [/SUP], Guido Garosi[SUP] 5 [/SUP], Donata Medaglini[SUP] 1 [/SUP]



Affiliations
Abstract

Introduction: Individuals with comorbidities, such as chronic kidney disease and hemodialysis patients (HDP), are particularly susceptible to severe COVID-19 and to its complications. Furthermore, their immune response to vaccines is impaired, requiring tailored vaccination strategies. In this study, we investigated through transcriptomic profiling the immune response heterogeneity of HDP vaccinated with two doses of mRNA BNT162b2 vaccine.
Methods: Transcriptomic analyses were conducted in peripheral blood mononuclear cells (PBMC) collected from HDP and healthy controls (HC) before and 7 days after each dose. The HDP were stratified into high- and low-responders based on their humoral response after the second dose.
Results: Significant differences in gene expression related to B cell abundance and regulation, CD4 T cell proliferation, and inflammation pathways were observed at baseline and day 7 between HDP-low responders and HC, while the HDP high-responders displayed an intermediate expression profile for these genes.
Discussion: Results were consistent with the known immunologic alterations occurring in HDP cohorts related to lymphopenia, chronic inflammation, and dysregulated proliferation of CD4+. Our analyses identified an early transcriptional signature correlated with a diminished immune response in HDP low-responders, highlighting the importance of conducting a characterization of immunocompromised cohorts.

Keywords: EPO (Erythropoietin); SARS-CoV2 vaccine; biomarkers; hemodialysis; transcriptomics.

 
Back
Top Bottom